Drug Approval | April 02, 2024
AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer
Application based on results from the TROPION-Breast01 Phase III trial
Application based on results from the TROPION-Breast01 Phase III trial
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
To accelerate the development of next-generation radioconjugates to treat cancer
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
The validations confirm the completion of the applications and commence the scientific review process
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Subscribe To Our Newsletter & Stay Updated
